Old drugs still work! Oral etoposide in a relapsed medulloblastoma
Medulloblastoma is the most common malignant brain tumor in children. Approximately 30% of children with medulloblastoma will progress or relapse despite being treated. New therapies have been proposed in recent years, including high-dose chemotherapy, immunotherapy, and targeted therapy. However, the best treatment for these patients remains unclear, and in this situation prognosis is poor. Oral etoposide has been used as a single agent or in combination for treating relapsed brain tumors since the 1990s. We report an 8-year-old patient with recurrent metastatic medulloblastoma who had an excellent response after treatment with oral etoposide, maintaining a great quality of life. As clinicians, we must always try to include our patients in clinical trials; however, when this is not possible, we should not forget that “old drugs” such as oral etoposide may work in some patients, with a good response of the tumor, and what is most important, providing the patient with a good quality of life.
KeywordsOral etoposide Relapsed medulloblastoma Chemotherapy Children
Magnetic resonance imaging
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 1.Scheinemann K, Bouffet E (2015) Pediatric neuro-oncology. Springer. Chapter 12. Embryonal brain tumors (127–138)Google Scholar
- 2.Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC (2017) Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 18(7):958–971CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27(11):573–581CrossRefPubMedGoogle Scholar
- 17.Esbenshade AJ, Kocak M, Hershon L et al (2017) A phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): a report from the Children’s Oncology Group. Pediatr Blood Cancer 64(6):1–8CrossRefGoogle Scholar
- 21.Le Deley MC, Leblanc T, Shamsaldin A et al (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societé Française d’Oncologie Pédiatrique. J Clin Oncol 21(6):1074–1081CrossRefPubMedGoogle Scholar
- 22.Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472CrossRefPubMedGoogle Scholar